Intensity Therapeutics Reports Wider Third-Quarter Net Loss
Intensity Therapeutics said higher research and development spending increased its third-quarter net loss year over year, citing costs for the INVINCIBLE-3 trial, a new INT230-6 manufacturing batch and salary-related expenses. The company also resumed new patient enrollment activities in the trial.
Story updates
12:45:07 PM UTC
SquawkNews
New patient enrollment activities resumed in a limited number of U.S. sites in the soft tissue sarco
12:46:07 PM UTC
SquawkNews
Intensity Therapeutics 3Q Loss/Shr $1.09 >INTS
12:46:07 PM UTC
SquawkNews
Intensity Therapeutics 3Q Loss $3.54M >INTS
12:46:59 PM UTC
SquawkNews
Intensity Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
12:47:10 PM UTC
SquawkNews
Intensity Therapeutics reported a Q3 2026 net loss of $3.5M versus $2.7M a year earlier and cash of $8.5M at September 30. Enrollment resumed in its Phase 3 INVINCIBLE-3 and Phase 2 INVINCIBLE-4 studies; preliminary data from 14 INVINCIBLE-4 patients showed pCR rates of 71% and 42% in the respectiv…
Intensity Therapeutics reported a wider third-quarter net loss year over year as research and development spending rose, led by increased INVINCIBLE-3 trial costs, a new INT230-6 manufacturing batch, and higher salary-related costs. The company resumed new patient enrollment activities in the trial…